UK Oncology Market Analysis: Cancer Diagnostics and Cancer Treatment Drugs, Therapy, Applications (Blood Cancer, Lung Cancer, Colorectal Cancer, Breast Cancer, Liver Cancer, Bladder Cancer, Head & Neck Cancer, Prostate Cancer, and Others), Region: London, South East England, East of England, Northwest and rest of United Kingdom

License Type

UK Oncology market size is estimates to be $XX million in 2022. In 2015, there were almost 300,000 cancer cases reported in England or 822 cases per day. The newly diagnosed cancer cases have continued to rise. More than half of all cancer registrations in England for all ages are still made up of breast (15.4%), prostate (13.4%), lung (12.5%), and colorectal (11.6%) cancers. Males registered 153,061 more cancer cases than females did (146,862). women are less diagnosed with cancer than men at major cancer locations. This data characteristic has been present consistently since earlier registration years. The majority of cancer cases in 2015 were diagnosed among persons 65 and older, who accounted for 65.2% of all cancer cases.

In the UK, there are approximately 167,000 cancer-related fatalities every year, or nearly 460 per day (2017-2019). Around 78,000 cancer-related deaths among females occur in the UK each year (2017-2019). Around 89,200 men die from cancer each year in the UK (2017-2019).

Lung cancer is a significant contributor to the overall UK oncology market. There are about 48,500 new cases of lung cancer in the UK yearly, or more than 130 cases every day. lung cancer is among the most prevalent malignancy, lung cancer account for about 13% of all cancer new cases.

In the UK, there are around 55,900 new instances of breast cancer annually, or more than 150 cases every day (2016-2018). breast cancer is one of the most prevalent malignancies in the UK, accounting for about 15% of all cancer new cases.

In the UK, there are around 6,200 new instances of liver cancer per year, or 17 cases every day (2016-2018)., liver cancer ranks as one of the most prevalent cancers in the UK, making up about 2% of all cancer new cases.

In the UK, bladder cancer will be discovered in 1 in 133 women and 1 in 50 men throughout their lifetimes. In the UK, bladder cancer diagnoses are presented in 49% of instances.

In the UK, there are around 52,300 new instances of prostate cancer year, or more than 140 cases every day (2016-2018). Prostate cancer is the most prevalent cancer in men in the UK, with over 52,300 new cases per year (2016-2018). In the UK, 27 percent of new occurrences of male cancer are caused by prostate cancer (2016-2018).

The disparities between digestive and respiratory malignancies in the UK can be partially explained by the socioeconomic distribution of some risk factors (such as smoking, alcohol, and food). National strategies aimed at raising the country’s educational level as well as “unbalanced” health promotion initiatives directed towards social groups with the highest prevalences of risk factors may be crucial in minimizing socioeconomic disparities in cancer risk.

UK Oncology Market by States

London Telemedicine Market
South East England Telemedicine Market
East of England Telemedicine Market
Northwest Telemedicine Market
Rest of United Kingdom

UK oncology market has been spilt into regions namely London, South East England, East of England, Northwest and rest of United Kingdom.

UK Oncology Market Segments

Datavagyanik has covered each oncology in detail in terms of market size, sales volume, growth forecast. The segment and sub segment level categorization covered in the report are:

Cancer Diagnostics
- Biopsy
- Imaging
- Immunohistochemistry
- Tumor Biomarkers Test
- In Situ Hybridization
- Liquid Biopsy
Cancer Treatment Drugs (Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar, and Others)
- Cancer Treatment Therapy
  - Targeted Therapy
  - Chemotherapy
  - Hormonal Therapy
  - Immunotherapy
  - Others
- Applications
  - Blood Cancer
  - Lung Cancer
  - Colorectal Cancer
  - Breast Cancer
  - Liver Cancer
  - Bladder Cancer
  - Head & Neck Cancer
  - Prostate Cancer
  - Others

Key questions answered in the UK Oncology Market Analysis Report:

What is the overall oncology market size in UK and how is the demand rising and what is market for each cancer type (Blood Cancer, Lung Cancer, Colorectal Cancer, Breast Cancer, Liver Cancer, Bladder Cancer, Head & Neck Cancer, Prostate Cancer, Others)?
What is the market size for cancer diagnostics (Biopsy, Imaging, Immunohistochemistry, Tumor, Biomarkers Test, In Situ Hybridization, Liquid Biopsy) in UK?
What is the market size for cancer treatment drugs (Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar, and Others) in UK?
What is the market size for cancer treatment by therapy (Targeted Therapy, Chemotherapy, Hormonal Therapy, Immunotherapy, Others) in UK?
Who are the top market players by market share, in each product segment?
Which is the fastest growing business/ product segment?
What should be the business strategies and Go to Market strategies?

Oncology in UK: Report Deliverables

Summary Statistics
- Oncology in UK Market Attractiveness Analysis

Oncology Diagnostics Market
Oncology Drugs
Therapies/Treatment Type

Oncology in UK Market Analysis, by Segment (state level analysis)
- Overview
- Historical Market size ($Million), (2017 – 2021)
- Market size ($Million), and Forecasts (2022 – 2027)
Market Analysis by Segment (state level analysis)
- End Users (Hospitals, Diagnostics Centers, others)
- Application (Blood Cancer, Lung Cancer, Colorectal Cancer, Breast Cancer, Liver Cancer, Bladder Cancer, Head & Neck Cancer, Prostate Cancer, Others)
Region wise analysis

London revenue & volume (Cancer Diagnostics and Cancer Treatment Drugs, Therapy)
South East England revenue & volume (Cancer Diagnostics and Cancer Treatment Drugs, Therapy)
East of England revenue & volume (Cancer Diagnostics and Cancer Treatment Drugs, Therapy)
Northwest revenue & volume (Cancer Diagnostics and Cancer Treatment Drugs, Therapy)
Rest of UK revenue & volume (Cancer Diagnostics and Cancer Treatment Drugs, Therapy)